News Details

Manila, March 2026. The Philippines has notified a draft administrative order that would establish a more detailed and structured framework for the application, issuance, renewal, variation, and monitoring of Certificates of Good Manufacturing Practice (GMP) Compliance for both local and foreign pharmaceutical manufacturers. The proposal would replace the earlier, narrower approach centered on foreign drug manufacturers and move toward a unified system covering broader pharmaceutical manufacturing activities, including active pharmaceutical ingredients intended for distribution and sale.

What the draft regulation does

The draft sets out a comprehensive regulatory framework for GMP compliance certification in the Philippines. It governs how manufacturers apply for certification, the documentary requirements they must submit, the assessment routes available to the Food and Drug Administration (FDA), the validity and renewal of certificates, and the grounds for approval, disapproval, and follow-up regulatory action.

The measure is positioned as a more complete GMP control system for pharmaceutical establishments and products, aimed at strengthening regulatory oversight and aligning Philippine practice more closely with internationally accepted standards.

Relevant background and regulatory context

The draft should be read in the context of the Philippines’ existing legal and regulatory framework under Republic Act No. 3720, as amended, and Republic Act No. 9711. It also builds on Administrative Order No. 2013-0022, titled Guidelines for Current Good Manufacturing Practice (cGMP) Clearance and Inspection of Foreign Drug Manufacturers.

That earlier 2013 order focused on foreign drug manufacturers and GMP clearance. By contrast, the new draft expands the framework to both local and foreign pharmaceutical manufacturers and formally reframes the authorization as a Certificate of GMP Compliance rather than the older GMP clearance concept. It also introduces a more explicit structure for inspection pathways, document review, post-approval responsibilities, and renewal rules.

Who would be covered

The draft would apply to all local and foreign pharmaceutical manufacturers, whether government-owned or private, as well as their duly authorized distributors or importers. It would also apply to manufacturers and importers of active pharmaceutical ingredients intended for distribution and sale.

Pharmaceutical traders are not covered under this GMP framework and would remain subject to the separate rules on good distribution and storage practices.

Two application pathways: desktop assessment and on-site inspection

A key feature of the proposal is the creation of two GMP certification pathways.

Category I, or desktop assessment, would apply where the manufacturer can rely on specified GMP evidence from recognized regulatory authorities or international schemes. These include manufacturers from PIC/S member countries, manufacturers covered by the ASEAN Mutual Recognition Arrangement on GMP, manufacturers with WHO prequalification inspection outcomes, and certain lower-risk applications and minor variations.

Category II, or on-site inspection, would apply where the manufacturer does not qualify for desktop assessment, or where an existing GMP-compliant manufacturer seeks approval for a new or additional product line not previously covered.

This structure would allow the Philippine FDA to rely on external regulatory evidence in some cases, while preserving direct inspection authority for higher-risk or non-qualifying cases.

Documentary requirements become more formalized

The draft sets out a more detailed list of required documents depending on the application category. These include an accomplished application form with declaration and undertaking, a site master file, contract agreements between relevant parties, GMP evidence issued by recognized authorities, inspection reports, and proof of payment of the applicable fees.

For on-site inspections, additional documentation such as the quality manual and latest inspection reports would be required. The draft also states that all submitted documents must be in English, with translations supported by a signed declaration confirming accuracy.

Fees, filing discipline, and pre-assessment controls

The proposal formalizes the use of the FDA eServices Portal System for filing and communication and places responsibility for filing on the qualified person representing the applicant. It also introduces a pre-assessment stage to check completeness before full evaluation proceeds.

Applications would not move forward without proof of payment of the pre-assessment fee, and both pre-assessment and application fee payments would be subject to strict validity periods. Non-payment within the prescribed period would result in cancellation or disapproval, requiring a fresh filing.

Inspection powers and post-market consequences

The draft confirms that the FDA may conduct on-site, remote, or hybrid GMP inspections, depending on the circumstances. In countries with security or emergency concerns, virtual inspection may be used. The FDA also reserves the right to require inspections and collect samples at any time if safety or quality concerns arise.

Where the FDA finds critical deficiencies, applications may be disapproved. For major or other deficiencies, the manufacturer may be required to submit a corrective and preventive action plan. The draft also links GMP non-compliance to possible recalls, seizures, suspensions, revocations, cancellations, and other regulatory or legal actions.

Certificate validity, renewals, and late filing consequences

The draft generally provides for a GMP certificate validity period of up to three years, with the exact basis depending on whether the application proceeded through desktop assessment or on-site inspection.

Renewal applications would need to be filed six months before expiry. Automatic renewal would not apply. If a renewal application is filed after expiry, surcharges and penalties may apply, and prolonged failure to renew could cause the certificate to lapse entirely, with the application then treated as a new initial filing. In such cases, the previous FDA-issued certificate would no longer be acceptable as GMP evidence.

Variation rules also become more explicit

The proposal requires manufacturers, distributors, and importers to notify the FDA of variations or changes affecting the manufacturer and covered product categories. For foreign manufacturing facilities, variation filings would need to be supported by proof of approval from the national regulatory authority in the country of origin.

This creates a clearer lifecycle compliance obligation beyond the initial certificate issuance.

Why this matters for industry

For pharmaceutical companies supplying the Philippine market, the draft signals a more rigorous and systematized GMP compliance regime. It would likely increase the importance of maintaining current GMP evidence, aligning contractual and site documentation, monitoring renewal timelines closely, and preparing for both reliance-based review and direct inspection scenarios.

For foreign manufacturers in particular, the proposal is important because it moves the Philippines away from a framework focused mainly on foreign cGMP clearance and toward a broader compliance system with clearer expectations on validity, variations, inspections, and regulatory consequences.

Next steps

The notified draft indicates a proposed entry into force of 15 May 2026, although adoption is still pending. Comments are invited until 15 April 2026. If adopted in its current direction, the measure would become one of the more important recent regulatory updates for pharmaceutical market access and manufacturing compliance in the Philippines.